WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Saturday, November 18, 2017 
Add Press Release News | News Feeds Feeds | Email This News Email


Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2017
Friday, November 10, 2017

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Pipeline Review, H2 2017

LONDON, Nov. 10, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4120482



Summary
According to the recently published report 'Hepcidin - Pipeline Review, H2 2017'; Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation of ferroportin leading to the retention of iron in iron exporting cells and decreased flow of iron into plasma. It controls the major flows of iron into plasma, absorption of dietary iron in the intestine and recycling of iron by macrophages.

The report 'Hepcidin - Pipeline Review, H2 2017' outlays comprehensive information on the Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Report covers products from therapy areas Hematological Disorders, Genetic Disorders, Immunology and Oncology which include indications Hemochromatosis, Thalassemia, Acute Inflammation, Anemia, Anemia in Chronic Kidney Disease (Renal Anemia), Iron Deficiency Anemia, Polycythemia Vera and Sickle Cell Disease.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)
- The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Download the full report: https://www.reportbuyer.com/product/4120482

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/hepcidin-liver-expressed-antimicrobial-peptide-1-or-putative-liver-tumor-regressor-or-hamp---pipeline-review-h2-2017-300553792.html

SOURCE ReportBuyer



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav China Digital TV to Hold 2017 Annual General Meeting on December 29, 2017 | Nov 17, 2017
Nav ASGARD Partners & Co. Announces Engagement by Burst Inc. as Strategic and Capital Markets Advisor | Nov 17, 2017
Nav Upland Software Announces Largest Acquisition to Date, Raises Guidance | Nov 17, 2017
Nav NINJA BLENDER - SOLLUME ESTHÉ Distributor G&J Completes Venture Company Certification by Ministry of SMEs and Startups (MSS) in South Korea | Nov 17, 2017
Nav Global Medical Devices Market 2017 - US Versus International Sales | Nov 17, 2017
Nav Tuniu Announces Management Change and Preliminary Results for the Third Quarter of 2017 | Nov 17, 2017
Nav Global Hydrogels Applications and Markets Report 2017 | Nov 17, 2017
Nav Global $172.6 Billion Therapies Market for Resistant and Recurrent Metastatic Cancer, 2022 | Nov 17, 2017
Nav Global $5.8 Billion Botanical Extracts Market 2017-2022 - Emergence of New Application Areas Accordance With Changing Consumption Trends | Nov 17, 2017
Nav United States Agricultural Machinery Market 2017-2021 - Establishment of Combined Solutions for Optimized Agriculture Practices | Nov 17, 2017
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News